Cancer Drug Parity Act of 2025
Rep. Grothman Introduces Cancer Drug Parity Act to Lower Costs for Oral Chemotherapy
Legislative Progress
Key Points
Impact Analysis
Personal Impact
Life & Work
Small businesses that offer group health plans would need to ensure their plans comply with the new oral cancer drug cost-sharing parity rules. While this could slightly increase plan costs (as insurers absorb more of the oral drug expense), the impact on any individual employer is likely small since cancer treatment claims are relatively rare. However, for smaller risk pools, even one high-cost claim adjustment could affect premiums.
Disabilities
Milestones
Referred to the House Committee on Education and Workforce.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
Votes
No votes have been recorded for this legislation yet.
Related News
3 articlesTHU AM News: Rockwell Automation report sheds light on life sciences manufacturing trends; Marquette Law School Poll finds greater concern about PFAS in water supply
The Cancer Drug Parity Act would require health insurers to cover oral cancer treatments 'on the same level' as traditional intravenous therapies. It expands protections to patients with private insurance whose health care is regulated at the federal level, addressing high out-of-pocket costs.
New Medicare changes ease cost burden for cancer drugs
While discussing the Inflation Reduction Act's $2,000 cap on Medicare drug costs, the report notes that the Cancer Drug Parity Act remains a critical legislative goal to equalize costs for oral and IV treatments for those in private plans not covered by the new Medicare caps.
The Pharmacoeconomics of Oral and Self-Administered Cancer Treatments
This analysis explores the 'oral parity' issue, noting that oral drugs are often covered under pharmacy benefits with high coinsurance, while IV drugs fall under medical benefits. It highlights the Cancer Drug Parity Act as the primary federal solution to this cost discrepancy.
Source Information
Document Type
Congressional Bill
Official Title
Cancer Drug Parity Act of 2025
Data Sources
Sponsor
Cosponsors
(27)Analysis generated by AI. Always verify with official sources.